Background: The distinction between Cushing’s disease (Cushing’s syndrome dependent on adrenocorticotropic hormone (ACTH)-secreting tumors of pituitary origin) and pseudo-Cushing’s states (Cushingoid features and hypercortisolism sometimes present in alcoholic, depressed or obese subjects) can present a diagnostic challenge in clinical endocrinology. Recently, the availability of a highly sensitive immunofluorometric assay for the measurement of total prostate-specific antigen (PSA) provided the possibility to measure serum PSA levels in women. Interestingly, PSA gene expression and protein production has been found to be upregulated by steroid hormones, such as androgens, glucocorticoids, mineral corticoids and progestins. In fact, serum total PSA concentrations appear to be higher in female patients with Cushing’s disease than in normal women. We wondered whether a similar phenomenon also occurs in pseudo-Cushing’s state. Methods: In order to answer this question, we compared the serum total PSA levels measured in 10 female subjects with alcohol-dependent pseudo-Cushing’s state with those observed in 8 female patients with Cushing’s disease and in 15 age-matched healthy women. Serum testosterone, ACTH and cortisol, and 24-hour urinary cortisol levels were measured; cortisol suppression after dexamethasone was also tested in all subjects. Results: The basal serum levels of ACTH and cortisol were significantly lower in normal subjects than in patients with Cushing’s disease or pseudo-Cushing’s state; these latter groups showed similar basal hormonal values. Dexamethasone administration was unable to suppress serum cortisol levels in 5 subjects with Cushing’s disease and 6 subjects with pseudo-Cushing’s state. Serum testosterone values in the group with Cushing’s disease were higher than in the other groups. No differences were observed between pseudo-Cushing’s and normal subjects. Serum total PSA levels were significantly higher in women with Cushing’s disease than in subjects with pseudo-Cushing’s state and normal controls; these latter groups showed similar PSA values. When serum total PSA and testosterone levels were considered together, a significant positive correlation was observed in the group with Cushing’s disease, but not in the other groups. Conclusions: These data indicate that the steroid milieu responsible for the elevation in serum PSA in women with Cushing’s disease is not present in subjects with alcohol-dependent pseudo-Cushing’s state, suggesting the possible use of PSA as a marker of differentiation between these pathological conditions in women.

Keywords:
Cushing’s disease, Prostate-specific antigen, Pseudo-Cushing’s state, alcohol dependent, Adrenocorticotropic hormone-secreting tumors
1.
Newell-Price J, Trainer P, Besser M, Grossman A: The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998;19:647–672.
2.
Lamberts SWJ, Klijn JGM, de Jong FH, Birkenhager JC: Hormone secretion in alcohol-induced pseudo-Cushing’s syndrome. Differential diagnosis with Cushing disease. JAMA 1979;242:1640–1643.
3.
Kapcala LP: Alcohol-induced pseudo-Cushing’s syndrome mimicking Cushing disease in a patient with adrenal mass. Am J Med 1987;82:849–856.
4.
Cook DM: Alcohol-induced pseudo-Cushing’s syndrome. Endocrinologist 1994;4:160–166.
5.
Diamandis EP, Yu H: New biological functions of prostate specific antigen? J Clin Endocrinol Metab 1995;80:1515–1517.
6.
Melegos DN, Yu H, Ashok M, et al: Prostate-specific antigen in female serum. A potential new marker of androgen excess. J Clin Endocrinol Metab 1997;82:777–780.
7.
Escobar-Morreale MF, Serrano-Gotarredona J, Avila S, et al: The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998;83:2580–2584.
8.
Negri C, Tosi F, Dorizzi R, et al: Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: Evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 2000;85:81–84.
9.
Obiezu CV, Scorilas A, Magklara A, et al: Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1558–1561.
10.
Luke MC, Coffey DS: Human androgen receptors binding to the androgen response element of prostate specific antigen. J Androl 1994;15:49–51.
11.
Magklara A, Grass L, Diamandis EP: Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 2000;59:263–270.
12.
Manetti L, Lupi I, Bogazzi F, et al: Prostate specific antigen is increased in female patients with Cushing’s disease. J Endocrinol Invest 2002;25:RC29–RC31.
13.
Spitzer RZ, Williams JBW, Gibbon M, et al: Structured Clinical Interview for DSM III R patients. Version (SCID-P). New York, Biometric Research Department New York Psychiatric Institute 1988, p 42.
14.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
15.
Coiro V, Volpi R, Capretti L, et al: Desmopressin and exarelin tests in alcohol-induced pseudo-Cushing’s syndrome. J Intern Med 2000;247:667–673.
16.
Yu H, Diamandis EP, Zarghami N, et al: Induction of prostatic specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994;32:291–300.
17.
Beato M: Gene regulation by steroid hormones. Cell 1989;56:335–344.
18.
Van Thiel DH, Lester R: Alcoholism: Its effect on hypothalamic pituitary gonadal function. Prog Hepatol 1976;71:318–327.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.